Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on December 19, 2023. The filing addresses a significant regulatory milestone regarding the Company's Shield blood test, a product designed to screen for colorectal cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statement data.
Material Changes and Events
- Regulatory Update: The U.S. Food and Drug Administration (FDA) has tentatively scheduled a review of the Company's Premarket Approval (PMA) application for the Shield blood test.
- Review Date: The FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on March 28, 2024.
- Confirmation Status: The specific date and meeting details remain subject to confirmation by the FDA and publication in the Federal Register.
Outlook, Risks, and Management Commentary
Management has announced the tentative scheduling of the advisory committee meeting as a key step in the approval process for the Shield test. The primary contingency noted is that the meeting date and details are not final until confirmed by the FDA. No specific financial guidance or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the official publication of the March 28, 2024, meeting date in the Federal Register.
- Monitor the outcome of the FDA Medical Devices Advisory Committee meeting for the Shield blood test.
- Review the full text of the press release filed as Exhibit 99.1 for additional context.